Further understanding of the intricate interplay between TGFβ receptors, Smad3, Snail and EZH2 will not only increase our knowledge of epigenetic and pathogenic processes in diverse diseases such as diabetes and cancer, but will point towards new therapeutic approaches focused on the exploitation and control of cellular plasticity (Fig. 7). This evidence concerns the gene SMAD3 and diabetes mellitus.